Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)

SHA:600664 Revenue

Harbin Pharmaceutical Group had revenue of 4.06B CNY in the quarter ending September 30, 2026, with 4.11% growth. This brings the company's total for the last twelve months to 16.30B, up 2.22% year-over-year. In the year 2025, Harbin Pharmaceutical Group had annual revenue of 15.96B, down -1.31%. That makes Harbin Pharmaceutical Group the 4,382nd largest company in the world by revenue and 556th in China.

• Revenue (ttm): 16.30B
• Revenue Growth: +2.22%
• P/S Ratio: 0.86
• Revenue / Employee: 1.62M
• Employees: 10,039
• Market Cap: 13.98B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Business Tips 10.34B 64.3%
• Industrial 5.74B 35.7%

By Geography

Chart

• China 14.41B 90.3%
• Overseas 1.56B 9.7%

Fiscal year ended Dec 31, 2025 See the full SHA:600664 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	15.96B	-211.79M	-1.31%
Dec 31, 2024	16.18B	719.28M	4.65%
Dec 31, 2023	15.46B	1.65B	11.93%
Dec 31, 2022	13.81B	1.01B	7.86%
Dec 31, 2021	12.80B	2.01B	18.66%

Data Source: S&P Global Market Intelligence Last updated: Oct 26, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 2, 2026

Data Sources Report a data error